Avery Vicky M, Bashyam Sridevi, Burrows Jeremy N, Duffy Sandra, Papadatos George, Puthukkuti Shyni, Sambandan Yuvaraj, Singh Shivendra, Spangenberg Thomas, Waterson David, Willis Paul
Medicines for Malaria Venture MMV, ICC - Block G, 3rd Floor, route de Pré-Bois 20, PO Box 1826, 1215 Geneva 15, Switzerland.
Malar J. 2014 May 27;13:190. doi: 10.1186/1475-2875-13-190.
In view of the need to continuously feed the pipeline with new anti-malarial agents adapted to differentiated and more stringent target product profiles (e.g., new modes of action, transmission-blocking activity or long-duration chemo-protection), a chemical library consisting of more than 250,000 compounds has been evaluated in a blood-stage Plasmodium falciparum growth inhibition assay and further assessed for chemical diversity and novelty.
The selection cascade used for the triaging of hits from the chemical library started with a robust three-step in vitro assay followed by an in silico analysis of the resulting confirmed hits. Upon reaching the predefined requirements for selectivity and potency, the set of hits was subjected to computational analysis to assess chemical properties and diversity. Furthermore, known marketed anti-malarial drugs were co-clustered acting as 'signposts' in the chemical space defined by the hits. Then, in cerebro evaluation of the chemical structures was performed to identify scaffolds that currently are or have been the focus of anti-malarial medicinal chemistry programmes. Next, prioritization according to relaxed physicochemical parameters took place, along with the search for structural analogues. Ultimately, synthesis of novel chemotypes with desired properties was performed and the resulting compounds were subsequently retested in a P. falciparum growth inhibition assay.
This screening campaign led to a 1.25% primary hit rate, which decreased to 0.77% upon confirmatory repeat screening. With the predefined potency (EC₅₀ < 1 μM) and selectivity (SI > 10) criteria, 178 compounds progressed to the next steps where chemical diversity, physicochemical properties and novelty assessment were taken into account. This resulted in the selection of 15 distinct chemical series.
A selection cascade was applied to prioritize hits resulting from the screening of a medium-sized chemical library against blood-stage P. falciparum. Emphasis was placed on chemical novelty whereby computational clustering, data mining of known anti-malarial chemotypes and the application of relaxed physicochemical filters, were key to the process. This led to the selection of 15 chemical series from which ten confirmed their activity when newly synthesized sample were tested.
鉴于需要持续为研发流程提供适应差异化且更严格目标产品轮廓(例如新作用模式、传播阻断活性或长效化学保护)的新型抗疟药物,一个由超过25万种化合物组成的化学文库已在恶性疟原虫血液期生长抑制试验中进行评估,并进一步评估其化学多样性和新颖性。
用于从化学文库中筛选活性化合物的分级筛选流程始于一个稳健的三步体外试验,随后对所得的确认活性化合物进行计算机分析。在达到预定义的选择性和效力要求后,对活性化合物集进行计算分析以评估化学性质和多样性。此外,已知的上市抗疟药物作为“路标”在由活性化合物定义的化学空间中进行共聚类。然后,对化学结构进行深入评估以识别当前或曾经是抗疟药物化学项目重点的骨架。接下来,根据宽松的物理化学参数进行优先级排序,并寻找结构类似物。最终,合成具有所需性质的新型化学类型,并随后在恶性疟原虫生长抑制试验中对所得化合物进行重新测试。
此次筛选活动的初步命中率为1.25%,在确认性重复筛选后降至0.77%。根据预定义的效力(EC₅₀ <1 μM)和选择性(SI >10)标准,178种化合物进入下一步,在这一步中考虑了化学多样性、物理化学性质和新颖性评估。这导致选择了15个不同的化学系列。
应用了一个分级筛选流程来对针对恶性疟原虫血液期的中型化学文库筛选所得的活性化合物进行优先级排序。重点在于化学新颖性,其中计算聚类、已知抗疟化学类型的数据挖掘以及宽松物理化学过滤器的应用是该过程的关键。这导致选择了15个化学系列,当对新合成的样品进行测试时,其中十个证实了其活性。